Overview

alemtuzumab


'alemtuzumab' can also refer to...

alemtuzumab

Coronary ischemia related to alemtuzumab therapy

Early outcomes using alemtuzumab induction in lung transplantation

Tuberculosis Due to Mycobacterium bovis after Alemtuzumab Administration

Cryptococcal Immune Reconstitution Inflammatory Syndrome following Alemtuzumab Therapy

Comment on alemtuzumab and inclusion body myositis

Reply: Comment on alemtuzumab and inclusion body myositis

Long-term efficacy of alemtuzumab in polymyositis

Infectious Complications Associated with Alemtuzumab Use for Lymphoproliferative Disorders

Fever, Shock, and Pancytopenia in a Patient Treated with Alemtuzumab

Fever, Shock, and Pancytopenia in a Patient Treated with Alemtuzumab

Hepatosplenic gammadelta T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine

Opportunistic Infections in 547 Organ Transplant Recipients Receiving Alemtuzumab, a Humanized Monoclonal CD-52 Antibody

Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis

Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity

Alemtuzumab, Fludarabine and Melphalan as a Conditioning Therapy in Severe Aplastic Anemia and Hypoplastic Myelodysplastic Syndrome—Single Center Experience

Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis

Immunity 12 years after alemtuzumab in RA: CD5+ B-cell depletion, thymus-dependent T-cell reconstitution and normal vaccine responses

Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study

 

More Like This

Show all results sharing this subject:

  • Clinical Pharmacology and Therapeutics

GO

Show Summary Details

Quick Reference

A humanized rat monoclonal antibody directed against CD52, used in the treatment of B-cell chronic lymphocytic leukaemia and as an immunosuppressive prior to transplant surgery.

Subjects: Clinical Pharmacology and Therapeutics.


Reference entries

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.